XTL Biopharma ends NeuroNOS acquisition LOI

XTL Biopharmaceuticals reports that its previously announced letter of intent with Beyond Air, Inc. for a potential acquisition of NeuroNOS Ltd. has lapsed.

Rhea-AI Filing Summary

XTL Biopharmaceuticals reports that its previously announced letter of intent with Beyond Air, Inc. for a potential acquisition of NeuroNOS Ltd. has lapsed. The letter of intent expired on March 9, 2026 because the parties did not sign a definitive agreement.

Beyond Air notified XTL on the same date that it considers the letter of intent terminated, and that both sides are released from further obligations, other than provisions that expressly survive termination, such as confidentiality. This update confirms that the contemplated NeuroNOS transaction is not moving forward under the expired agreement.

Insights

Biopharma M&A Analyst

A planned NeuroNOS acquisition by XTL has been halted after the LOI expired.

XTL Biopharmaceuticals had been exploring an acquisition of NeuroNOS Ltd. under a letter of intent with Beyond Air, Inc. That preliminary agreement expired on March 9, 2026 without a definitive transaction being signed, so negotiations under that framework have ended.

Beyond Air also confirmed termination of the letter of intent and released both parties from further obligations, except surviving clauses such as confidentiality. Future dealings around NeuroNOS, if any, would require new arrangements, and details are not outlined in this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did XTL Biopharmaceuticals (XTLB) disclose in this March 2026 Form 6-K?

XTL Biopharmaceuticals disclosed that its letter of intent with Beyond Air, Inc. for a potential acquisition of NeuroNOS Ltd. has expired. The parties did not enter a definitive agreement and are now released from most obligations under the letter of intent.

Is XTL Biopharmaceuticals (XTLB) still pursuing the NeuroNOS Ltd. acquisition?

Under this specific letter of intent, XTL is no longer pursuing the NeuroNOS Ltd. acquisition. The LOI with Beyond Air, Inc. expired on March 9, 2026, without a definitive agreement, and the parties confirmed termination of obligations except for surviving provisions like confidentiality.

When did the XTL–Beyond Air letter of intent for NeuroNOS Ltd. expire?

The letter of intent between XTL Biopharmaceuticals and Beyond Air, Inc. regarding a potential acquisition of NeuroNOS Ltd. expired on March 9, 2026. It lapsed by its terms because the parties did not execute a definitive agreement by that date, ending the contemplated transaction framework.

What obligations remain after termination of the XTL and Beyond Air NeuroNOS LOI?

After termination, XTL and Beyond Air are released from further obligations under the LOI, except provisions that expressly survive, including confidentiality obligations. This means most deal-related commitments end, while confidentiality and any other designated surviving clauses continue to bind the parties.

Does the Form 6-K mention any financial terms for the XTL–NeuroNOS transaction?

The report does not describe any specific financial terms for the contemplated NeuroNOS acquisition. It focuses on confirming that the letter of intent with Beyond Air, Inc. expired on March 9, 2026, and that the parties ended their obligations apart from certain surviving provisions like confidentiality.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/10/2026 - 04:05 PM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

For the month of March, 2026

Commission File Number: 001-36000

XTL Biopharmaceuticals Ltd. 

(Translation of registrant’s name into English)

5 Badner St.

Ramat Gan,
4365603, Israel 

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒          Form 40-F ☐

As previously disclosed in the Report of Foreign Private Issuer on Form 6-K filed with the SEC on January 13, 2026, XTL Biopharmaceuticals Ltd. (the “Company” or “XTL”) entered into a letter of intent (the “LOI”) with Beyond Air, Inc. (“XAIR”) regarding a proposed acquisition transaction involving NeuroNOS Ltd., a private biopharmaceutical company incorporated under the laws of the State of Israel. On March 9, 2026, the LOI expired by its terms, as the parties have not entered into a definitive agreement. On March 9, 2026, XAIR also notified the Company that it considers the LOI terminated as of March 9, 2026, and that the parties are released from any further obligations under the LOI other than those provisions that expressly survive termination, including the confidentiality obligations.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: March 10, 2026	XTL BIOPHARMACEUTICALS LTD.
	By:	/s/ Noam Band
		Noam Band
		Chief Executive Officer

2